Globus Medical, Inc. (NYSE:GMED - Free Report) - Investment analysts at Roth Capital dropped their Q3 2025 earnings per share estimates for Globus Medical in a research report issued to clients and investors on Friday, August 8th. Roth Capital analyst J. Wittes now forecasts that the medical device company will earn $0.78 per share for the quarter, down from their prior forecast of $0.80. The consensus estimate for Globus Medical's current full-year earnings is $3.44 per share. Roth Capital also issued estimates for Globus Medical's Q4 2025 earnings at $0.92 EPS, FY2025 earnings at $3.24 EPS, Q1 2026 earnings at $0.79 EPS, Q2 2026 earnings at $0.93 EPS, Q3 2026 earnings at $0.99 EPS, Q4 2026 earnings at $1.08 EPS, FY2026 earnings at $3.79 EPS and FY2027 earnings at $4.06 EPS.
Globus Medical (NYSE:GMED - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The medical device company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.76 by $0.10. The company had revenue of $745.34 million for the quarter, compared to the consensus estimate of $738.91 million. Globus Medical had a net margin of 13.58% and a return on equity of 10.65%. The firm's revenue was up 18.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.75 EPS.
A number of other equities research analysts have also issued reports on GMED. Barclays reissued an "overweight" rating on shares of Globus Medical in a research note on Tuesday, June 10th. Truist Financial reduced their target price on Globus Medical from $80.00 to $68.00 and set a "hold" rating on the stock in a research note on Monday, May 12th. Needham & Company LLC reissued a "hold" rating on shares of Globus Medical in a research note on Monday, July 21st. JMP Securities restated a "market perform" rating on shares of Globus Medical in a report on Tuesday, May 27th. Finally, Wall Street Zen raised shares of Globus Medical from a "hold" rating to a "buy" rating in a research note on Saturday. Five research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Globus Medical currently has an average rating of "Moderate Buy" and an average target price of $87.64.
Read Our Latest Stock Analysis on Globus Medical
Globus Medical Stock Performance
GMED opened at $58.84 on Monday. The stock has a market cap of $7.97 billion, a price-to-earnings ratio of 22.63, a P/E/G ratio of 1.70 and a beta of 1.20. The stock's 50 day moving average price is $57.08 and its 200-day moving average price is $68.26. Globus Medical has a one year low of $51.79 and a one year high of $94.93.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in GMED. Summitry LLC raised its holdings in shares of Globus Medical by 40.4% in the 2nd quarter. Summitry LLC now owns 5,819 shares of the medical device company's stock valued at $343,000 after purchasing an additional 1,673 shares in the last quarter. Intech Investment Management LLC boosted its stake in shares of Globus Medical by 134.3% during the second quarter. Intech Investment Management LLC now owns 11,843 shares of the medical device company's stock valued at $699,000 after purchasing an additional 6,788 shares in the last quarter. SG Americas Securities LLC increased its holdings in Globus Medical by 1,864.8% during the second quarter. SG Americas Securities LLC now owns 52,539 shares of the medical device company's stock valued at $3,101,000 after buying an additional 49,865 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its holdings in Globus Medical by 6.7% during the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 29,019 shares of the medical device company's stock valued at $1,713,000 after buying an additional 1,832 shares during the period. Finally, Banco Bilbao Vizcaya Argentaria S.A. raised its stake in Globus Medical by 7.0% in the second quarter. Banco Bilbao Vizcaya Argentaria S.A. now owns 117,690 shares of the medical device company's stock worth $6,946,000 after buying an additional 7,711 shares in the last quarter. 95.16% of the stock is currently owned by institutional investors.
Globus Medical announced that its board has authorized a share repurchase program on Thursday, May 15th that authorizes the company to buyback $500.00 million in shares. This buyback authorization authorizes the medical device company to reacquire up to 6.3% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's leadership believes its shares are undervalued.
Globus Medical Company Profile
(
Get Free Report)
Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Globus Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Globus Medical wasn't on the list.
While Globus Medical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.